ERBB2 and breast carcinoma: Considering tumor biology, (likely) deleterious mutation carriers presented the following distribution at the time of the first breast cancer diagnosis: 18% TNBC (n = 2), 36% HR pos HER2-neg (n = 4), and 45% HER2-pos (n = 5) (Fig. 1).